Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals reported a larger quarterly loss as it invests heavily in cancer drug development, but ended the period with substantial cash. For the three months ended March 31, 2026, net loss was $53.1 million compared with $30.4 million a year earlier, driven mainly by higher research and development expenses of $49.2 million and general and administrative expenses of $8.8 million.
Total assets were $530.6 million, including $505.3 million in cash, cash equivalents and marketable securities. Operating cash outflow was $46.0 million, largely offset by $41.9 million of net proceeds from an at-the-market stock program. Management believes existing cash, securities and available debt capacity will fund the current operating plan for at least 12 months. As of May 7, 2026, common shares outstanding were 87.3 million, excluding 13.6 million shares issuable upon exercise of pre-funded warrants.
Olema Oncology reported first quarter 2026 results highlighted by heavy investment in late-stage breast cancer programs and a strong cash position. Cash, cash equivalents, and marketable securities were $505.3 million as of March 31, 2026. Net loss was $53.1 million, compared with $30.4 million a year earlier, reflecting increased spending on clinical development and corporate activities.
GAAP R&D expenses rose to $49.2 million from $30.6 million, while GAAP G&A expenses increased to $8.8 million from $4.2 million, driven in part by higher non-cash stock-based compensation. Non-GAAP R&D and G&A expenses were $42.7 million and $5.2 million, respectively. The company expects top-line data from its pivotal Phase 3 OPERA-01 trial this fall, continues enrollment in the Phase 3 OPERA-02 trial, and plans for an anticipated first commercial launch next year.
Olema Pharmaceuticals, Inc. entered a seven-year lease with KR Oyster Point II, LLC for a new headquarters totaling approximately 38,176 square feet across two floors in South San Francisco. The company plans to relocate its corporate headquarters to this space by December 2026 as existing San Francisco leases expire between December 2026 and January 2027.
The Lease sets total base rent of $12,361,188.00 for Phase I and $6,145,463.76 for Phase II during the initial term, net of rent abatement. Olema must provide a cash security deposit of $427,546.80 and may terminate once at month 60 by paying a $1,716,240.96 fee. The agreement includes a five-year extension option and a right of first offer on additional space, while the landlord funds specified build-out work and can terminate if Olema fails to cure certain breaches.
Olema Pharmaceuticals director Raman Prakash received two stock option grants as equity compensation. The awards cover a combined 27,061 shares of common stock at an exercise price of $14.59 per share, expiring on April 27, 2036.
Options on 24,150 shares vest in full on June 11, 2026, while options on 2,911 shares vest in 36 equal monthly installments starting April 28, 2026. All vesting is conditioned on Prakash’s continuous service with the company.
Olema Pharmaceuticals, Inc. director Raman Prakash has filed an initial insider ownership report. This filing establishes his status as a reporting person for the company and, based on the provided data, does not list any share purchases, sales, or other transactions.
Olema Pharmaceuticals is holding its 2026 Annual Meeting of Stockholders virtually on June 17, 2026 at 8:00 a.m. PT. Stockholders of record as of April 23, 2026, when 87,346,132 common shares were outstanding, are eligible to vote.
Investors will vote on electing four Class III directors to serve until the 2029 annual meeting, approving on an advisory basis the compensation of named executive officers, and ratifying Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Olema Oncology has appointed Dr. Prakash Raman as a Class II director, effective April 28, 2026, with his term running until the company’s 2028 annual stockholders’ meeting. The board determined he is an independent director under Nasdaq rules and reported no related-party transactions.
Under Olema’s non-employee director compensation policy, Dr. Raman received a nonstatutory stock option to purchase 24,150 shares, vesting in 36 equal monthly installments, and a separate nonstatutory option for 2,911 shares that vests in full on June 11, 2026, in each case conditioned on continued service. Olema highlighted his extensive business development and leadership experience across multiple biopharmaceutical companies as it advances palazestrant in two Phase 3 trials and OP-3136 in a Phase 1 study.
Olema Pharmaceuticals reports beneficial ownership filings by Invus and related persons. As of March 16, 2026, Invus Public Equities directly held 3,898,500 shares and Avicenna Life Sci Master Fund directly held 563,449 shares. The filing states 87,156,961 Shares outstanding as of March 11, 2026. The cover pages show each reporting person’s sole voting and dispositive power counts and calculated ownership percentages (for example, 4.5% and 0.6% on cover pages). Signatories certify the holdings were not acquired to change control.
OLMA reported Rule 144 sale notices for Common Stock by Shane W. Kovacs. The filing lists multiple sales between 01/13/2026 and 03/11/2026, including a sale of 241,999 shares on 03/09/2026 for $3,254,934.55. The report provides per‑trade share counts and gross proceeds for each listed transaction.